공시 • Apr 07
Imagion Biosystems Limited, Annual General Meeting, May 26, 2026 Imagion Biosystems Limited, Annual General Meeting, May 26, 2026. 공시 • Feb 04
Imagion Biosystems Ltd. Lodges IND with FDA for Phase 2 Trial of MagSense HER2 Targeting Imaging Agent Imagion Biosystems Ltd. announced that the company has progressed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its MagSense®? targeted imaging agent. Following FDA approval, the company expects to start a Phase 2 clinical trial with the imaging agent for the detection of nodal metastases in HER2+ breast cancer patients. MagSense®? is a first-of-its-class molecular MRI (mMRI) platform technology that uses iron oxide nanoparticles with custom moieties (e.g., antibodies) to target specific disease biomarkers. Unlike general purpose contrast agents, MagSense®? particles are only detected when and where cancer is present. Using MRI, the presence of iron oxide produces a significant, identifiable change in image contrast, empowering clinicians with better information for diagnosis and treatment planning. Based on historical FDA review timelines, the company anticipates enrollment for the Phase 2 trial could begin as early as first quarter 2026. The company has selected and engaged all required strategic trial partners to manage the study and has begun the process of clinical study site engagement and progressing study logistics in compliance with Good Clinical Practices. 공시 • Sep 01
Imagion Biosystems Limited Appoints Nina Webster as Non- Executive Director, Effective 1 September 2025 Imagion Biosystems Limited announced the appointment of Dr. Nina Webster as a Non-Executive Director to the Board, effective 1 September 2025. Dr. Webster brings to the Board a wealth of experience in the Australian ASX listed pharmaceutical industry, holding leadership roles over a thirty-year period. She currently serves as Managing Director and Chief Executive Officer of Dimerix Ltd. Formerly the Commercial Director for Acrux Limited and Director of Commercialisation and Intellectual Property for Immuron Limited, Nina brings to IBX vast experience in investor relations, strategic planning, and scientific and operational execution. Dr. Webster holds a Ph.D in Pharmaceutics, a Bachelor's degree in Pharmacology, a Master's degree in Intellectual Property Law and an Executive MBA and currently also serves as Non-Executive Chairperson for SYNthesis BioVentures and as Non-Executive Director for Linear Clinical Research Limited. The addition of Dr. Webster to the IBX Board of Directors will further strengthen the Board's capabilities as the Company continues to execute on its strategic objectives to develop and gain regulatory approval for its pipeline of MagSense® molecular imaging technologies. 공시 • Aug 04
Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million. Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 223,333,333
Price\Range: AUD 0.015
Discount Per Security: AUD 0.0009
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 10,000,000
Price\Range: AUD 0.015
Discount Per Security: AUD 0.0009
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing 공시 • Apr 01
Imagion Biosystems Limited, Annual General Meeting, May 30, 2025 Imagion Biosystems Limited, Annual General Meeting, May 30, 2025. 공시 • Dec 13
Imagion Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 0.125 million. Imagion Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 0.125 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 6,250,000
Price\Range: AUD 0.02
Discount Per Security: AUD 0.0012
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing 공시 • Nov 08
Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 0.125 million. Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 0.125 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 6,250,000
Price\Range: AUD 0.02
Discount Per Security: AUD 0.0012
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing 공시 • Aug 01
Imagion Biosystems Limited Announces Board Changes Imagion Biosystems Limited announced that Ms Melanie Leydin will join the Board as a Non-Executive Director with the appointment effective from 31 July 2024. Ms Leydin has over 25 years' experience in the accounting profession and over 15 years as a company secretary with extensive experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, re-organization of Companies and shareholder relations. IBX announced that, effective immediately before the conclusion of the General Meeting scheduled on 22 August 2024, Michael Harsh, David Ludvigson and Mark Van Astan, will cease to hold office. (That is, all of the directors who were in office at the time the directors' report (as included in the Company's annual financial report for the financial year ended 31 December 2023) was approved, other than Robert Proulx who acts as Executive Chairman and Managing Director, will cease to hold office). 공시 • May 06
Imagion Biosystems Limited, Annual General Meeting, May 31, 2024 Imagion Biosystems Limited, Annual General Meeting, May 31, 2024, at 10:01 E. Australia Standard Time. Location: K&L Gates Melbourne, Level 25, 525 Collins Street Melbourne Victoria Australia Agenda: To receive and consider the Financial Report of the Company and its controlled entities and the related Directors' and Auditor's Reports in respect of the financial year ended 31 December 2023; to consider adoption of the Remuneration Report; to approve re-Election of Director; and to consider other matters. 공시 • Nov 15
Imagion Biosystems Limited Approves Election of Isaac Bright as Director Imagion Biosystems Limited announced that at its Extraordinary General Meeting held on 13 November 2023, the shareholders approved Election of Director - Dr. Isaac Bright. 공시 • Jun 19
Imagion Biosystems Limited Announces CEO Changes Imagion Biosystems Limited announced it has appointed Isaac Bright, MD as CEO, effective 20 June 2023. Dr. Bright is a results-focused business leader and brings to Imagion over 20 years of experience as a health industry executive and venture capitalist in medical technology, biopharmaceuticals, and oncology-based molecular diagnostics. Dr. Bright most recently served as Co-Founder, CEO, and Chairman of RubrYc Therapeutics Inc. before its trade sale to iBio Inc. in September 2022. Prior to launching RubrYc, Dr. Bright was Chief Business Officer for molecular diagnostics innovator HealthTell Inc., driving its trade sale to iCarbonX, concomitant with RubrYc’s launch in 2018. Prior to that, Dr. Bright served as VP, Corporate Development for Synthetic Biologics Inc. and consulting Chief Business Officer for synthetic biology innovator musebio Inc. (currently Incripta Inc.) as it secured its $23 million Series B Preferred financing. Dr. Bright was the first American Partner investing with Merieux Developpement (currently, Merieux Equity Partners) from 2012 through 2016, during which he helped the firm raise €150 million Merieux Participations 2 fund. With Merieux, Dr. Bright led investments and Board representation for Imaginab Inc., Kalila Medical Inc. until its acquisition by Abbott, and Twist Bioscience before its IPO. Dr. Bright’s startup experience began as he built and led QuantaLife Inc.’s Corporate Development and Molecular Diagnostics functions from 2009-2011, leading to QuantaLife’s acquisition by Bio-Rad Laboratories Inc. Previously, Dr. Bright served as Sr. Associate, Corporate Development and Director, Business Development - Neuromodulation for global medtech leader Medtronic. Dr. Bright earned his bachelor’s degree in biochemistry from Pepperdine University, his medical degree from the Stanford University School of Medicine and was a Howard E. Mitchell Fellow earning his MBA from the Wharton School at the University of Pennsylvania. The hiring of Dr. Bright follows from the recent announcement on 28 April 2023 regarding the plan for Bob Proulx to retire from the role of CEO, remaining as Chairman of the Board. 